Morgan Stanley analyst Judah Frommer initiated coverage of Agomab (AGMB) with an Overweight rating and $28 price target The firm says the company developing ontunisertib and AGMB-447 for fibrotic conditions. While the data are early for both programs, the stock’s risk/reward is skewed to the upside heading into 2026 based, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGMB: